Head and Neck Cancers Case Control Study of HIV Positive Compared to Negative Patients in a Ugandan Population Sample

Kamulegeya Adriane; Otiti Jeff

doi:doi:10.11648/j.ijcoms.20170304.11

| Peer-Reviewed

Head and Neck Cancers Case Control Study of HIV Positive Compared to Negative Patients in a Ugandan Population Sample

Kamulegeya Adriane, Otiti Jeff

Published in International Journal of Clinical Oral and Maxillofacial Surgery (Volume 3, Issue 4)

Received: 23 October 2017 Accepted: 13 November 2017 Published: 21 December 2017

Views: Downloads:

Download PDF

Share This Article

Twitter
Linked In
Facebook

Abstract

Increased availability of highly active anti-retroviral therapy (HAART) has led to a change in the spectrum of neoplastic diseases affecting people living with HIV. Some cancers such as invasive cervical carcinoma and anal cancers have not changed or instead risen while others such as Kaporsi’s sarcoma have seen a sharp decline. The aim of this study was to compare clinical findings at presentation between HIV positive and Negative patients with head and neck cancers using a retrospective case control design. The study was done at the Uganda cancer Institute by performing a manual match of records in the head and neck cancer database at a ratio of 1:2 cases: controls. The matching was done on the age group, gender and diagnosis. Clinical and demographic characteristics between HIV positive and HIV negative head and neck cancer patients were compared using chi square and a multinomial model including ECOG performance score, stage, grade and duration group was run. In the multinomial regression only duration group was significant with the HIV positive patients being more likely to present after a longer duration of the symptoms than HIV negative patients (OR=0.42 CI 0.20-0.86 p=0.02). The data does not show statistically significant difference between HIV positive and HIV negative head and neck cancer patients in terms of presentation at time of diagnosis except for duration of symptoms group. This study clearly demonstrates the need for more research on head and neck cancer in Africa in the context of HIV/AIDS, since the reasons for the high HIV prevalence among this cohort of patients hasn’t been established.

Published in	International Journal of Clinical Oral and Maxillofacial Surgery (Volume 3, Issue 4)
DOI	10.11648/j.ijcoms.20170304.11
Page(s)	20-25
Creative Commons	This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.
Copyright	Copyright © The Author(s), 2017. Published by Science Publishing Group

Keywords

Head and Neck Cancers, HIV/AIDS, Cancer Risk Factors

References

[1]	K. Djawe, K. Buchacz, L. Hsu, M Chen, R. M. Selik, C. Rose, T. Williams, J. T. Brooks, and S. Schwarcz, “Mortality Risk After AIDS-De fi ning Opportunistic Illness Among HIV-Infected Persons San Francisco 1981-2012,” J. Infect. Dis., vol. 212, pp. 1366–75, 2015.
[2]	M. Bower, A. Palfreeman, M. Alfa-Wali, C. Bunker, F. Burns, D. Churchhill, S. Collins, K. Cwynarski, S. Edwards, P. Fields, and K. Fife, “British HIV Association guidelines for HIV-associated malignancies 2014 British HIV Association guidelines for HIV-associated malignancies 2014,” HIV Med., vol. 15, no. Suppl. 2, pp. 1–92, 2014.
[3]	M. R. Pinzone, F. Florica, M. Di Rosa, G. Malaguarnera, L. Malaguarnera, B. Cacopardo, G. Zanghi, and G. Nunnari, “Non-AIDS-defining cancers among HIV-infected people,” Eur. Med. Pharmacol. Sci., vol. 16, pp. 1377–1388, 2012.
[4]	J. F. Deeken, A. Tjen-a-looi, M. A. Rudek, C. Okuliar, M. Young, R. F. Little, and B. J. Dezube, “The Rising Challenge of Non – AIDS-Defining Cancers in HIV-Infected Patients,” Clin. Infect. Dis., vol. 55, no. 9, pp. 1228–1235, 2012.
[5]	R. T. Mitsuyasu, “Non–AIDS-Defining Malignancies in HIV,” Top HIV Med, vol. 16, no. 4, pp. 117–121, 2008.
[6]	R. Newton, J. Ziegler, V. Beral, E. Mbidde, L. Carpenter, H. Wabinga, S. Mbulaiteye, P. Appleby, G. Reeves, and H. Jaffe, “A case-control study of human immunodeficiency virus infection and cancer in adults and children residing in Kampala, Uganda.,” Int. J. Cancer, vol. 92, no. 5, pp. 622–7, Jun. 2001.
[7]	B. S. Sylla and C. P. Wild, “cancer research and control offer to the continent ?,” Int J Cancer, vol. 130, pp. 245–250, 2012.
[8]	UNAIDS, “Global AIDS update,” in GARPR, 2016, pp. 1–12.
[9]	IAS, “Global Fact Sheet: HIV/AIDS,” in AIDS 2014 Stepping up the pace, 2014, pp. 1–20.
[10]	M. N. Mignogna, S. Fedele, and L. lo Russo, “The World Cancer Report and the burden of oral cancer,” Eur. J. Cancer Prev., vol. 13, no. 2, pp. 139–142, 2004.
[11]	S. Warnakulasuriya, “Global epidemiology of oral and oropharyngeal cancer,” Oral Oncol., vol. 45, no. 4–5, pp. 309–316, 2008.
[12]	B. Purgina, L. Pantanowitz, and R. R. Seethala, “A Review of Carcinomas Arising in the Head and Neck Region in HIV- Positive Patients,” Patholog. Res. Int., vol. 2011, p. Article ID 469150, 2011.
[13]	E. N. Fedrizzi, J. K. Laureano, C. Schlup, M. O. Campos, and M. E. Menezes, “Human Papillomavirus ( HPV ) Infection in HIV Positive Women of Florianópolis, State of Santa Catarina, Brazil,” J Bras Doencas Sex Tansm, vol. 23, no. 4, pp. 210–214, 2011.
[14]	C. Queiroz, A. G. Travassos, E. Studart, J. Bouzas, and A. Filho, “Prevalence of Human Papilloma Virus in HIV-Positive and HIV-Negative Patients in the State of Bahia. A Pilot Study,” The Brazillian journalofinfectiousdiseases, vol. 8, no. 5, pp. 356–362, 2004.
[15]	M. Stevenson, F. Talavera, C. D. Braden, and G. D. Petruzzelli, “Head and Neck Cancer Staging TNM classification of Head and Neck cancer,” http://emedicine.medscape.com/article/2007181?overview, 2017. [Online]. Available: http://emedicine.medscape.com/article/2007181?overview. [Accessed: 14-Apr-2017].
[16]	M. M. Gounder, R. D. Carvajal, J. Anand, C. D. Braden, and J. E. Harris, “Soft Tissue Sarcoma Staging,” http://emedicine.medscape.com/article/2006584?overview, 2017..
[17]	S. Marur and A. A. Forastiere, “Head and Neck Squamous Cell Carcinoma: Update on Epidemiology, Diagnosis, and Treatment,” Mayo Clin. Proc., vol. 91, no. 3, pp. 386–396, 2016.
[18]	A. Yakubu and O. Mabogunje, “Skin Cancer of the Head and Neck in Zaria, Nigeria,” Acta Oncol. (Madr)., vol. 34, no. 4, pp. 469–471, 2017.
[19]	O. B. Lilly-tariah, A. O. Somefun, and W. L. Adeyemo, “Current evidence on the burden of head and neck cancers in Nigeria,” Head Neck Oncol., vol. 8, p. 1: 14, 2009.
[20]	D. Gisselquist, R. Rothenberg, J. Potterat, and E. Drucker, “HIV infections in sub-Saharan Africa not explained by sexual or vertical transmission,” Int. J. STD AIDS, vol. 13, pp. 657–666, 2002.
[21]	F. Butt, M. L. Chindia, F. Rana, and F. Machingo, “Pattern of head and neck malignant neoplasms in HIV infected patients in Kenya,” Int. J. Oral Maxillofac. Surg., vol. 10, pp. 907–911, 2008.
[22]	Uganda AIDS Commission, “The Uganda HIV and AIDS country progress report July 2015 - June 2016,” 2016.
[23]	A. Kamali, L. Mary, J. A. Grover, R. Pool, A. Ruberantwari, and A. Ojwiya, “Seven-year trends in HIV-1 infection rates, and changes in sexual behaviour, among adults in rural Uganda,” AIDS, vol. 14, pp. 427–434, 2000.
[24]	Uganda Ministry of Health and ICF Intetnational, “2011 Uganda AIDS Indicator Survey key findings,” Calverton Maryland, 2012.
[25]	E. Kakande, R. Byaruhaga, and A. Kamulegeya, “Head and neck squamous cell carcinoma in a Ugandan population : a descriptive epidemiological study,” J Afr Cancer, vol. 2, pp. 219–225, 2010.
[26]	E. Attar, S. Dey, A. Hablas, I. A. Seifeldin, M. Ramadan, L. S. Rozek, and A. S. Soliman, “Head and neck cancer in a developing country : A population-based perspective across 8 years,” Oral Oncol., vol. 46, no. 8, pp. 591–596, 2010.
[27]	L. Dobrossy, “Epidemiology of head and neck cancer : Magnitude of the problem,” Cancer Metasasis Rev., vol. 24, pp. 9–17, 2005.
[28]	UBOS, “Uganda Bureau of Statistics 2016, The National Population and Housing Census 2014 – Main Report, Kampala Uganda,” 2016.
[29]	K. Hjelm and F. Atwine, “Health-care seeking behaviour among persons with diabetes in Uganda : an interview study,” BMC Int. Health Hum. Rights, vol. 11, no. 1, p. 11, 2011.
[30]	D. I. Conway, M. Petticrew, H. Marlborough, J. Berthiller, M. Hashibe, and L. M. D. Macpherson, “Socioeconomic inequalities and oral cancer risk: a systematic review and meta-analysis of case-control studies.,” Int. J. Cancer, vol. 122, no. 12, pp. 2811–9, Jun. 2008.
[31]	C. D. Llewellyn, N. W. Johnson, and K. a Warnakulasuriya, “Risk factors for squamous cell carcinoma of the oral cavity in young people--a comprehensive literature review.,” Oral Oncol., vol. 37, no. 5, pp. 401–18, Jul. 2001.
[32]	N. W. Johnson and S. Warnakulasuriya, “Global Oral Health Inequalities in Incidence and Outcomes for Oral Cancer : Causes and Solutions,” Adv Dent Res, vol. 23, no. 2, pp. 237–246, 2011.
[33]	G. R. Kruse, D. R. Bangsberg, J. A. Hahn, E. Jessica, P. W. Hunt, C. Muzoora, J. P. Bennett, N. Jeffrey, and N. A. Rigotti, “Tobacco use among adults initiating treatment for HIV infectionin rural Uganda,” AIDS Behav, vol. 18, no. 7, pp. 1381–1389, 2015.
[34]	A. J. Christensen, P. J. Moran, S. L. Ehlers, K. Raichle, L. Karnell, and G. Funk, “Smoking and Drinking Behavior in Patients with Head and Neck Cancer : Effects of Behavioral Self-Blame and Perceived Control,” J. Behav. Med., vol. 22, no. 5, pp. 407–408, 1999.
[35]	JHU_CCP, “Alcohol Consumption in Uganda Literature Review March 2007,” Kampala, 2007.
[36]	A. E. Coghill, P. A. Newcomb, M. M. Madeleine, B. A. Richardson, I. Mutyaba, F. Okuku, W. Phipps, H. Wabinga, J. Orem, and C. Casper, “Contribution of HIV infection to mortality among cancer patients in Uganda,” AIDS, vol. 27, no. 18, pp. 2933–2942, 2015.

Cite This Article

Plain Text BibTeX RIS

APA Style

Kamulegeya Adriane, Otiti Jeff. (2017). Head and Neck Cancers Case Control Study of HIV Positive Compared to Negative Patients in a Ugandan Population Sample. International Journal of Clinical Oral and Maxillofacial Surgery, 3(4), 20-25. https://doi.org/10.11648/j.ijcoms.20170304.11

Copy | Download

ACS Style

Kamulegeya Adriane; Otiti Jeff. Head and Neck Cancers Case Control Study of HIV Positive Compared to Negative Patients in a Ugandan Population Sample. Int. J. Clin. Oral Maxillofac. Surg. 2017, 3(4), 20-25. doi: 10.11648/j.ijcoms.20170304.11

Copy | Download

AMA Style

Kamulegeya Adriane, Otiti Jeff. Head and Neck Cancers Case Control Study of HIV Positive Compared to Negative Patients in a Ugandan Population Sample. Int J Clin Oral Maxillofac Surg. 2017;3(4):20-25. doi: 10.11648/j.ijcoms.20170304.11

Copy | Download

@article{10.11648/j.ijcoms.20170304.11,
  author = {Kamulegeya Adriane and Otiti Jeff},
  title = {Head and Neck Cancers Case Control Study of HIV Positive Compared to Negative Patients in a Ugandan Population Sample},
  journal = {International Journal of Clinical Oral and Maxillofacial Surgery},
  volume = {3},
  number = {4},
  pages = {20-25},
  doi = {10.11648/j.ijcoms.20170304.11},
  url = {https://doi.org/10.11648/j.ijcoms.20170304.11},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ijcoms.20170304.11},
  abstract = {Increased availability of highly active anti-retroviral therapy (HAART) has led to a change in the spectrum of neoplastic diseases affecting people living with HIV. Some cancers such as invasive cervical carcinoma and anal cancers have not changed or instead risen while others such as Kaporsi’s sarcoma have seen a sharp decline. The aim of this study was to compare clinical findings at presentation between HIV positive and Negative patients with head and neck cancers using a retrospective case control design. The study was done at the Uganda cancer Institute by performing a manual match of records in the head and neck cancer database at a ratio of 1:2 cases: controls. The matching was done on the age group, gender and diagnosis. Clinical and demographic characteristics between HIV positive and HIV negative head and neck cancer patients were compared using chi square and a multinomial model including ECOG performance score, stage, grade and duration group was run. In the multinomial regression only duration group was significant with the HIV positive patients being more likely to present after a longer duration of the symptoms than HIV negative patients (OR=0.42 CI 0.20-0.86 p=0.02). The data does not show statistically significant difference between HIV positive and HIV negative head and neck cancer patients in terms of presentation at time of diagnosis except for duration of symptoms group. This study clearly demonstrates the need for more research on head and neck cancer in Africa in the context of HIV/AIDS, since the reasons for the high HIV prevalence among this cohort of patients hasn’t been established.},
 year = {2017}
}

Copy | Download

TY  - JOUR
T1  - Head and Neck Cancers Case Control Study of HIV Positive Compared to Negative Patients in a Ugandan Population Sample
AU  - Kamulegeya Adriane
AU  - Otiti Jeff
Y1  - 2017/12/21
PY  - 2017
N1  - https://doi.org/10.11648/j.ijcoms.20170304.11
DO  - 10.11648/j.ijcoms.20170304.11
T2  - International Journal of Clinical Oral and Maxillofacial Surgery
JF  - International Journal of Clinical Oral and Maxillofacial Surgery
JO  - International Journal of Clinical Oral and Maxillofacial Surgery
SP  - 20
EP  - 25
PB  - Science Publishing Group
SN  - 2472-1344
UR  - https://doi.org/10.11648/j.ijcoms.20170304.11
AB  - Increased availability of highly active anti-retroviral therapy (HAART) has led to a change in the spectrum of neoplastic diseases affecting people living with HIV. Some cancers such as invasive cervical carcinoma and anal cancers have not changed or instead risen while others such as Kaporsi’s sarcoma have seen a sharp decline. The aim of this study was to compare clinical findings at presentation between HIV positive and Negative patients with head and neck cancers using a retrospective case control design. The study was done at the Uganda cancer Institute by performing a manual match of records in the head and neck cancer database at a ratio of 1:2 cases: controls. The matching was done on the age group, gender and diagnosis. Clinical and demographic characteristics between HIV positive and HIV negative head and neck cancer patients were compared using chi square and a multinomial model including ECOG performance score, stage, grade and duration group was run. In the multinomial regression only duration group was significant with the HIV positive patients being more likely to present after a longer duration of the symptoms than HIV negative patients (OR=0.42 CI 0.20-0.86 p=0.02). The data does not show statistically significant difference between HIV positive and HIV negative head and neck cancer patients in terms of presentation at time of diagnosis except for duration of symptoms group. This study clearly demonstrates the need for more research on head and neck cancer in Africa in the context of HIV/AIDS, since the reasons for the high HIV prevalence among this cohort of patients hasn’t been established.
VL  - 3
IS  - 4
ER  -

Copy | Download

Author Information

Kamulegeya Adriane

Department of Dentistry, Makerere University, Kampala, Uganda
Otiti Jeff

Department of Surgery, Uganda Cancer Institute, Kampala, Uganda

Download PDF

Sections

Plain Text BibTeX RIS

APA Style

Kamulegeya Adriane, Otiti Jeff. (2017). Head and Neck Cancers Case Control Study of HIV Positive Compared to Negative Patients in a Ugandan Population Sample. International Journal of Clinical Oral and Maxillofacial Surgery, 3(4), 20-25. https://doi.org/10.11648/j.ijcoms.20170304.11

Copy | Download

ACS Style

Kamulegeya Adriane; Otiti Jeff. Head and Neck Cancers Case Control Study of HIV Positive Compared to Negative Patients in a Ugandan Population Sample. Int. J. Clin. Oral Maxillofac. Surg. 2017, 3(4), 20-25. doi: 10.11648/j.ijcoms.20170304.11

Copy | Download

AMA Style

Kamulegeya Adriane, Otiti Jeff. Head and Neck Cancers Case Control Study of HIV Positive Compared to Negative Patients in a Ugandan Population Sample. Int J Clin Oral Maxillofac Surg. 2017;3(4):20-25. doi: 10.11648/j.ijcoms.20170304.11

Copy | Download

@article{10.11648/j.ijcoms.20170304.11,
  author = {Kamulegeya Adriane and Otiti Jeff},
  title = {Head and Neck Cancers Case Control Study of HIV Positive Compared to Negative Patients in a Ugandan Population Sample},
  journal = {International Journal of Clinical Oral and Maxillofacial Surgery},
  volume = {3},
  number = {4},
  pages = {20-25},
  doi = {10.11648/j.ijcoms.20170304.11},
  url = {https://doi.org/10.11648/j.ijcoms.20170304.11},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ijcoms.20170304.11},
  abstract = {Increased availability of highly active anti-retroviral therapy (HAART) has led to a change in the spectrum of neoplastic diseases affecting people living with HIV. Some cancers such as invasive cervical carcinoma and anal cancers have not changed or instead risen while others such as Kaporsi’s sarcoma have seen a sharp decline. The aim of this study was to compare clinical findings at presentation between HIV positive and Negative patients with head and neck cancers using a retrospective case control design. The study was done at the Uganda cancer Institute by performing a manual match of records in the head and neck cancer database at a ratio of 1:2 cases: controls. The matching was done on the age group, gender and diagnosis. Clinical and demographic characteristics between HIV positive and HIV negative head and neck cancer patients were compared using chi square and a multinomial model including ECOG performance score, stage, grade and duration group was run. In the multinomial regression only duration group was significant with the HIV positive patients being more likely to present after a longer duration of the symptoms than HIV negative patients (OR=0.42 CI 0.20-0.86 p=0.02). The data does not show statistically significant difference between HIV positive and HIV negative head and neck cancer patients in terms of presentation at time of diagnosis except for duration of symptoms group. This study clearly demonstrates the need for more research on head and neck cancer in Africa in the context of HIV/AIDS, since the reasons for the high HIV prevalence among this cohort of patients hasn’t been established.},
 year = {2017}
}

Copy | Download

TY  - JOUR
T1  - Head and Neck Cancers Case Control Study of HIV Positive Compared to Negative Patients in a Ugandan Population Sample
AU  - Kamulegeya Adriane
AU  - Otiti Jeff
Y1  - 2017/12/21
PY  - 2017
N1  - https://doi.org/10.11648/j.ijcoms.20170304.11
DO  - 10.11648/j.ijcoms.20170304.11
T2  - International Journal of Clinical Oral and Maxillofacial Surgery
JF  - International Journal of Clinical Oral and Maxillofacial Surgery
JO  - International Journal of Clinical Oral and Maxillofacial Surgery
SP  - 20
EP  - 25
PB  - Science Publishing Group
SN  - 2472-1344
UR  - https://doi.org/10.11648/j.ijcoms.20170304.11
AB  - Increased availability of highly active anti-retroviral therapy (HAART) has led to a change in the spectrum of neoplastic diseases affecting people living with HIV. Some cancers such as invasive cervical carcinoma and anal cancers have not changed or instead risen while others such as Kaporsi’s sarcoma have seen a sharp decline. The aim of this study was to compare clinical findings at presentation between HIV positive and Negative patients with head and neck cancers using a retrospective case control design. The study was done at the Uganda cancer Institute by performing a manual match of records in the head and neck cancer database at a ratio of 1:2 cases: controls. The matching was done on the age group, gender and diagnosis. Clinical and demographic characteristics between HIV positive and HIV negative head and neck cancer patients were compared using chi square and a multinomial model including ECOG performance score, stage, grade and duration group was run. In the multinomial regression only duration group was significant with the HIV positive patients being more likely to present after a longer duration of the symptoms than HIV negative patients (OR=0.42 CI 0.20-0.86 p=0.02). The data does not show statistically significant difference between HIV positive and HIV negative head and neck cancer patients in terms of presentation at time of diagnosis except for duration of symptoms group. This study clearly demonstrates the need for more research on head and neck cancer in Africa in the context of HIV/AIDS, since the reasons for the high HIV prevalence among this cohort of patients hasn’t been established.
VL  - 3
IS  - 4
ER  -

Copy | Download